This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Roche Holding Performance degli utili passati
Criteri Il passato verificati 5/6
Gli utili di Roche Holding sono diminuiti a un tasso medio annuo di -8.5%, mentre il settore Pharmaceuticals ha visto gli utili diminuire a un tasso medio annuo di 2.7%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 0.4%. Il ritorno sul capitale proprio di Roche Holding è 36.4% e ha margini netti di 20.3%.
Informazioni chiave
-8.54%
Tasso di crescita degli utili
-6.83%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 16.33% |
| Tasso di crescita dei ricavi | -0.44% |
| Rendimento del capitale proprio | 36.43% |
| Margine netto | 20.33% |
| Prossimo aggiornamento sugli utili | 23 Jul 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • Mar 21
ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential
Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
Aggiornamento della narrazione • Mar 07
ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside
The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.Aggiornamento della narrazione • Feb 21
ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead
Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
Aggiornamento della narrazione • Feb 07
ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating
Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.Articolo di analisi • Feb 03
Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
Nuova narrazione • Feb 01
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Aggiornamento della narrazione • Jan 23
ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating
Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.Aggiornamento della narrazione • Jan 09
ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution
Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.Aggiornamento della narrazione • Dec 17
ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead
Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.Aggiornamento della narrazione • Dec 03
ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.Aggiornamento della narrazione • Nov 19
ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead
Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.Articolo di analisi • Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...Articolo di analisi • Jun 24
These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Nuova narrazione • Feb 04
Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
Nuova narrazione • Feb 02
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Roche Holding guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 63,356 | 12,880 | 13,767 | 12,535 |
| 30 Sep 25 | 63,422 | 11,155 | 13,786 | 12,847 |
| 30 Jun 25 | 63,488 | 9,429 | 13,804 | 13,158 |
| 31 Mar 25 | 62,942 | 8,853 | 13,739 | 13,265 |
| 31 Dec 24 | 62,395 | 8,277 | 13,674 | 13,372 |
| 30 Sep 24 | 61,488 | 9,448 | 13,510 | 13,377 |
| 30 Jun 24 | 60,581 | 10,619 | 13,346 | 13,381 |
| 31 Mar 24 | 60,511 | 11,059 | 13,416 | 13,463 |
| 31 Dec 23 | 60,441 | 11,498 | 13,486 | 13,545 |
| 30 Sep 23 | 61,486 | 11,263 | 13,690 | 13,669 |
| 30 Jun 23 | 62,530 | 11,028 | 13,894 | 13,793 |
| 31 Mar 23 | 64,172 | 11,725 | 13,793 | 13,696 |
| 31 Dec 22 | 65,814 | 12,421 | 13,691 | 13,599 |
| 30 Sep 22 | 66,716 | 13,539 | 13,262 | 13,592 |
| 30 Jun 22 | 67,617 | 14,657 | 12,833 | 13,585 |
| 31 Mar 22 | 66,734 | 14,294 | 12,405 | 13,804 |
| 31 Dec 21 | 65,850 | 13,930 | 11,977 | 14,022 |
| 30 Sep 21 | 63,974 | 13,975 | 12,037 | 13,747 |
| 30 Jun 21 | 62,098 | 14,019 | 12,097 | 13,472 |
| 31 Mar 21 | 61,221 | 14,157 | 12,026 | 13,019 |
| 31 Dec 20 | 60,343 | 14,295 | 11,954 | 12,566 |
| 30 Sep 20 | 61,361 | 13,626 | 12,289 | 12,382 |
| 30 Jun 20 | 62,378 | 12,957 | 12,624 | 12,198 |
| 31 Mar 20 | 63,065 | 13,227 | 12,904 | 12,061 |
| 31 Dec 19 | 63,751 | 13,497 | 13,183 | 11,923 |
| 30 Sep 19 | 62,736 | 12,654 | 13,275 | 11,702 |
| 30 Jun 19 | 61,721 | 11,810 | 12,933 | 11,480 |
| 31 Mar 19 | 60,609 | 11,155 | 12,800 | 11,337 |
| 31 Dec 18 | 59,497 | 10,500 | 12,667 | 11,194 |
| 30 Sep 18 | 58,611 | 10,483 | 12,641 | 11,005 |
| 30 Jun 18 | 57,725 | 10,465 | 12,615 | 10,815 |
| 31 Mar 18 | 56,736 | 9,549 | 12,322 | 10,672 |
| 31 Dec 17 | 55,746 | 8,633 | 12,029 | 10,529 |
| 30 Sep 17 | 54,961 | 9,154 | 11,148 | 10,411 |
| 30 Jun 17 | 54,176 | 9,675 | 10,266 | 10,293 |
| 31 Mar 17 | 53,406 | 9,626 | 10,305 | 10,172 |
| 31 Dec 16 | 52,636 | 9,576 | 10,343 | 10,050 |
| 30 Sep 16 | 52,109 | 9,332 | 10,655 | 9,975 |
| 30 Jun 16 | 51,581 | 9,087 | 10,966 | 9,900 |
| 31 Mar 16 | 50,992 | 8,975 | 10,953 | 9,678 |
| 31 Dec 15 | 50,403 | 8,863 | 10,940 | 9,455 |
| 30 Sep 15 | 50,364 | 8,908 | 10,978 | 9,305 |
| 30 Jun 15 | 50,324 | 8,953 | 11,004 | 9,155 |
| 31 Mar 15 | 50,095 | 9,143 | 10,924 | 9,068 |
Guadagni di qualità: ROG ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di ROG (20.3%) ROG sono più alti rispetto allo scorso anno (13.3%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di ROG sono diminuiti del 8.5% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di ROG nell'ultimo anno ( 55.6% ) supera la media quinquennale ( -8.5% all'anno).
Guadagni vs Settore: La crescita degli utili ROG nell'ultimo anno ( 55.6% ) ha superato la percentuale del settore Pharmaceuticals 15.3%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 36.4% ) di ROG è considerato alto.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/03/16 23:11 |
| Prezzo dell'azione a fine giornata | 2026/03/16 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Roche Holding AG è coperta da 43 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Mark Purcell | Barclays |